AYAnas Younes

Anas Younes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anas Younes has a total of 98 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Outcomes of HIV-positive lymphoma patients treated in the highly active antiretroviral therapy (HAART) era.

    by M. A. Fanale, K. Vigil, C. Lai, L. Feng, W. Dong, A. Younes, J. E. Romaguera, L. Fayad, F. B. Hagemeister, V. Mulanovich

    E18528 Background: The addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and intensification with R plus EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) have improved survival for AIDS-related non-Hodgkin lymphomas (NHL) (Bouë, F, et al, JCO, 2006 and Dunleavy, K, et al, Blood, 2010). R-HCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) alternating with R-MTX-ARA-C (methotrexate, cytarabine) is also highly effective for diffuse large B cell (DLBCL), Burkitt (BL), and Burkitt-like lymphomas (BLL) (Fayad, L, et al, ASCO, 2007 and Thomas, D, et al, Cancer, 2006). Furthermore, heightened responses are described for HIV-Hodgkin lymphoma (HL) patients treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and HAART (Xicoy, B, et al, Haematologica, 2007 and Sunil, M, et al, ASH, 2009). Methods: We conducted a retrospective study to evaluate outcomes and characteristics of HIV patients with newly diagnosed lymphoma treated at M.D. Anderson Cancer Center from 1998 to 2010. Results: 56 patients were identified, 93% were male, and all but 2 were on HAART. Median age was 42.5 and 73.2% had advanced stage disease. Diagnoses included DLBCL (36%), BL (29%), BLL (25%), T-cell lymphoma (3%), and HL (7%). 80% of the DLBCL, BL, and BLL patients received CHOP (n=11), HCVAD/MTX-ARA-C (n=17), or dose-adjusted (DA) EPOCH (n=8) with 77% incorporation of R. Complete remissions (CR) occurred in 94% of DLBCL, 77% of BL, and 69% of BLL patients. Only 1 HL patient treated with ABVD entered into CR. At a median follow-up of 21.6 months 5 patients relapsed and 19 died. Patients with a CD4 count >100 had superior progression free survival (PFS) and overall survival (OS) (p= 0.019, p=0.016). In addition, HIV diagnosis of < 6 months improved OS (p=0.012), and a non-significant improvement in PFS and OS was seen for BL and BLL patients with DA-EPOCH+/-R. Conclusions: Our data highlights that CD4 count at diagnosis and time from HIV diagnosis are important prognostic factors for patients with HIV and lymphoma. While a small group size and varied regimens are limiting factors, a trend towards decreased BL or BLL progression or relapse was seen with DA-EPOCH+/-R.

  • Phase II study of RCHOP with pegylated liposomal doxorubicin (DRCOP) for patients older than age 60 with untreated diffuse large B-cell lymphoma (DLBCL).

    by M. A. Rodriguez, J. Durand, A. B. Astrow, M. J. Bury, M. A. Fanale, F. B. Hagemeister, X. Huang, P. McLaughlin, S. S. Neelapu, B. Pro, et al.

    8053 Background: DLBCL is a common lymphoma of older adults, and a potentially curable disorder with the regimen RCHOP (Coiffier, et.al. NEJM,2002). Doxorubicin, a key drug in the regimen, has risk for cardiotoxicity, and thus of concern in older patients (pts) with higher incidence of cardiovascular (CV) disease. In breast cancer pts pegylated liposomal doxorubicin (D) has shown greater cardiac safety and similar efficacy to doxorubicin. We thus replaced doxorubicin with D in RCHOP (DRCOP). Methods: The regimen is: rituximab 375 mg/m2 IV day (d) 1; D 40 mg/m2 IV d 1; cyclophosphamide 750 mg/m2 IV d 1; vincristine 2 mg IV d 1 total dose; prednisone 100 mg/d p.o. d 1-5. Eligibility criteria were: > 60 years of age; untreated confirmed DLBCL (no discordant histology); Ann Arbor stage II-IV; baseline LVEF 50%. CV disease was permitted, if symptoms controlled, but consult at baseline by Cardiologist and at follow-up required. Troponin and brain natriuretic peptide (BNP) levels were monitored. Granulocyte growth factor support recommended (not required). Results: 80 pts total were enrolled on study; 79 were eligible and evaluable for response and toxicity. Characteristics of pts: age 61-94 years (median 71); 41 female. All had at least one cardiac risk factor. Responses were: 55 CR (69%); 14 PR. (17%) At a median follow-up of 2.7 years, 62 are alive (77%), with 78% progression free survival. There were 7 grade 3 adverse cardiac events: 1 drop in LVEF; 4 atrial arrhythmias (reversed); 1 hypotension (reversed); 1 chest pain (reversed). Troponin and BNP changes did not correlate with cardiac events. Other grade 3-4 non-hematologic events: 3 hand-foot syndrome; 4 fatigue; 2 DVT; 2 neuropathy. Only one death occurred on study due to pneumonia, non-neutropenic. The most common grade 3-4 toxicity events were hematologic. Conclusions: DRCOP is an active regimen. In this study of older pts with DLBCL, only one pt had drop in LVEF below normal. Other cardiac events were associated with underlying cardiac conditions, and were reversible. Liposomal doxorubicin should be considered in older patients. Comanagement by a Cardiologist during chemotherapy would be recommended.

  • Diffuse large B-cell lymphoma (DLBCL) with bone marrow (BM) involvement. clinical presentation, central nervous system (CNS) relapses, and outcomes of 121 patients treated at M. D. Anderson Cancer Center.

    by G. F. Perini, J. E. Romaguera, M. A. Rodriguez, B. Pro, A. Younes, N. H. Fowler, F. B. Hagemeister, F. Samaniego, L. W. Kwak, L. Fayad

    8072 Background: DLBCL with BM involvement is an uncommon condition, and it is suspected to be a more aggressive condition with worse outcome and increased risk for CNS. There is controversy about the best modality of treatment, and it is unclear if CNS prophylaxis should be performed in every patient. Methods: We examined a database of new patients seen at M. D. Anderson Cancer Center from 1998 to 2008. We found patients who had DLBCL and LBCL in the bone marrow (140 patients with discordant histology or HIV positive serology was excluded). Patient characteristics included 51% male, 73% elevated LDH, and 53% older than 60 years. IPI distribution included 4% low-risk, 16.5% IL, 37% IH, 40% high-risk (2% N/A). All patients received rituximab CHOP-like therapy, and 52% received intrathecal prophylaxis. Results: With a median follow-up of 3.5 years for living patients, 45 of patients have developed relapse, with a median time to progression of 3.1 years. The 5-year overall survival rate was 51%; survival was associated with IPI (p=0.02), with 46% of the patients with high-risk dying of their disease. There were 10 (9%) CNS relapses, 5 in the prophylaxis and 5 in the non-prophylaxis group. All CNS relapses occurred in patients with elevated serum LDH at diagnosis, and in those with high- intermediate (50%) and high (50%) scores. Risk IPI scores nine of 10 patients with CNS relapse died of their disease. There were no differences between the CNS relapse rates for high-risk patients whether they received CNS prophylaxis (10% CNS relapse) or not (16% CNS relapse, p=0.4). Conclusions: In our patients, DLBCL with BM involvement commonly presented with high-risk features, CNS relapses occurred mostly in patients with HI and H-IPI scores and elevated LDH. The role of CNS prophylaxis in prevention of relapse remains unclear and new options for prevention of CNS relapse should be considered. No significant financial relationships to disclose.

  • ABVD chemotherapy with interferon for advanced-stage classical Hodgkin's lymphoma: A 10-year follow-up study.

    by N. Batty, F. B. Hagemeister, J. E. Romaguera, M. A. Rodriguez, P. McLaughlin, F. Samaniego, A. Copeland, B. S. Dabaja, A. Younes

    8057 Background: Adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy has been the standard of care for Hodgkin's lymphoma (HL) for almost three decades. Previous studies demonstrated clinical benefit by combining interferon-alpha (IFN-α) with chemotherapy in newly diagnosed patients (pts) with follicular lymphoma (Sola-Celigny, N Eng J Med. 1993). In this study, we examined the safety and efficacy of the novel IFN-α and ABVD regimen in pts with advanced stage classical HL. Methods: Pts with newly diagnosed advanced stage classical HL were enrolled between July 1997 and March 2000 on Phase II trial of IFN-α + ABVD as initial therapy. The regimen consisted of 6 cycles of ABVD with concurrent IFN-α followed by XRT if indicated. The IFN-α was 6 million IU/ m2 administered subcutaneously on daily schedule for 3 days prior to starting chemotherapy and on day 4 the pts received IFN-α with ABVD. The courses were repeated every 2 weeks for a maximum of 12 doses. IFN-α, dose reduction was allowed for cytopenias. Outcome and baseline characteristics were reported. Results: Twenty eight newly diagnosed pts were eligible: Ann Arbor stages of II, III, IV, were 2 (7%), 9 (32%), and 17 (61%), respectively; International prognostic score (IPS) of 0-2 and ≥ 3 were 15 (54%) and 13 (46%), respectively. Fourteen pts (50%) underwent XRT. With a median follow-up of 10 years, the three-year event-free (EFS) and overall survival was 80% and 100%, respectively. The EFS at three years for pts with IPS of 0-2 and ≥ 3 were 78.5 % and 82.5%, respectively. The treatment was well tolerated with only three pts requiring dose reduction or discontinuation of IFN-α due to cytopenia. Conclusions: IFN-α + ABVD is well tolerated and has promising clinical activity, especially in pts with high IPS. Further development of this regimen is warranted. No significant financial relationships to disclose.

  • Prognostic value of serum CD44, ICAM-1 and VCAM-1 levels in patients with indolent non-Hodgkin’s lymphomas

    by N. Shah, F. Cabanillas, L. Feng, B. McIntyre, P. McLaughlin, M. A. Rodriguez, J. E. Romaguera, A. Younes, F. B. Hagemeister, L. Kwak, et al.

    8589 Background: Indolent lymphomas are the most common non-Hodgkin’s lymphomas (NHL). The cell adhesion molecules CD44, ICAM-1 and VCAM-1 present on lymphoma cells regulate cell-matrix interactions and lymphocyte migration. Elevated serum levels of CD44, ICAM-1 and VCAM-1 have been linked to poor prognosis in high grade lymphomas but their utility in low grade lymphomas remains undefined. Methods: To determine the clinical significance of CD44, ICAM-1 and VCAM-1 levels in patients with indolent NHL, we evaluated outcomes of 100 patients with newly diagnosed indolent NHL in relation to their CD44, VCAM-1 and ICAM-1 levels at presentation. All 3 markers were measured using commercially available ELISA kits. Median values of markers obtained from preliminary data analysis (CD44: 540 ng/ml, ICAM-1: 300 ng/ml VCAM-1: 1120 ng/ml) were used as cutpoints for analysis. Kaplan-Meier curves and the log-rank test were used to compare the difference in survival between the serum marker high and low groups. Multivariate analysis was done with Cox proportional hazard models. Tests were two-sided; p-values less than 0.05 were considered statistically significant. Results: Of 93 evaluable patients followed for a median of 15.2 years, 62% relapsed and 47% died. On univariate analysis elevated CD44, ICAM-1 and VCAM-1 were significantly associated with worse overall survival (OS) and relapse free survival (RFS). The predictive value of CD44, ICAM-1 and VCAM-1 for overall survival persisted even when only stage IV patients were analyzed (p<0.05). However, none of the serum markers were independent predictors of OS or RFS in a multivariate analysis that included the Follicular Lymphoma International Prognostic Index (FLIPI) score. Conclusions: Serum levels of the cell-adhesion molecules CD44, ICAM-1, and VCAM-1 are accurate predictors of outcome in patients with indolent NHL. The prognostic value is maintained within the sub-population of Stage IV patients. Unlike the FLIPI, which is limited to initial presentation, cell adhesion molecules may hold promise as serum biomarkers of response to therapy or progression of disease. No significant financial relationships to disclose.

  • The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma

    by M. J. Overman, L. Feng, B. Pro, P. McLaughlin, M. Hess, F. Samaniego, A. Younes, J. E. Romaguera, F. B. Hagemeister, L. Kwak, et al.

    Background: The benefit of adding rituximab to anthracycline-based therapy for follicular lymphoma grade 3 has not been studied. Patients and methods: We retrospectively reviewed the records of 45 patients with follicular grade 3 lymphoma who were treated with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) at The University of Texas MD Anderson Cancer Center. Response rate, failure-free survival (FFS), and overall survival (OS) were estimated and a historical comparison to CHOP-only-treated patients was made. Results: The International Prognostic Index (IPI) distribution was 47% low, 36% low intermediate, 13% high intermediate, and 4% high risk. The complete response rate was 96%. Forty-four of 45 patients are still alive. Median follow-up for the alive patients is 3.5 years. The 3-year FFS rate according to the IPI was 80% [95% confidence interval (CI) 64% to 100%] in low, 81% in low intermediate (95% CI 64% to 100%), and 50% (95% CI 25% to 100%) in high-intermediate/high-risk patient group. The addition of rituximab to CHOP improved both 5-year FFS, 71% (95% CI 58% to 87%) compared with 44% (95% CI 36% to 55%) with P value of 0.019, and 5-year OS, 98% (95% CI 93% to 100%) compared with 75% (95% CI 67% to 84%) with P value of 0.0034. Conclusion: The addition of rituximab to CHOP provided a high response rate and excellent early survival. Poor-risk patients continue to demonstrate a high rate of failure despite the use of rituximab.


  • Report of a phase II study of sphingosomal vincristine (SV) in patients with relapsed or refractory Hodgkin’s disease

    by L. Fayad, J. Romaguera, S. Hart, A. Younes, B. Pro, F. Hagemeister, P. McLaughlin, N. Dang, A. Pretti, A. Sarris, et al.

    6624 Background: Combination therapy is often not an option for multiple relapsed/refractory Hodgkin’s disease patients particularly after salvage high-dose chemotherapy and transplant. Vincristine is a cell cycle-specific anticancer drug, with established activity in Hodgkin’s disease. Sphingosomal vincristine (SV) is a novel sphingosome encapsulated formulation of vincristine, which presents several advantages over regular vincristine. SV has a longer half-life (15 hours versus 15 minutes), can be given uncapped, and shows accumulation in tumor sites in experimental models, providing a rationale for this cell-cycle specific agent. Methods: : SV was evaluated as a single agent for the treatment of patients with relapsed or refractory Hodgkin’s disease including those who failed auto or allogeneic transplantation. SV was administered at 2 mg/m2 (no dose capping) IV over 1 hour every 14 days. Patients were restaged every two cycles, responders continued two cycles beyond their best response to a maximum of 12 cycles. Results: Data is reported on 29 patients, 16 males and 13 females; median age was 32 years (range 19–58). Patients had a median of 4 prior chemotherapy regimens (range 2–10), 20 patients had also received prior radiation therapy and 22/29 pts (76%) failed prior transplant. Patients received a median of 4 cycles of SV (range 1–12). Among 27 patients evaluable, 8 responded with 2 CR, 2 CRu, and 4 PR for an overall response rate (ORR) of 30%. Other patients had stable disease (10 pts) or progression (9 pts). Among the responders the median number of prior therapy was 3 (range 2–6), 6/8 responders failed prior auto transplant. Grade 3 toxicity included: sensory neuropathy (2 pts), constipation (2 pts), pain/myalgia (2 pts), fatigue (2 pts), fever (w/o neutropenia) (1 pt). There was no grade 4 toxicity. Conclusions: SV is a promising agent for the treatment of relapsed/refractory Hodgkin’s disease with a 30% ORR in a heavily pretreated population. This therapy was well tolerated with mostly mild to moderate toxicities reported and few grade 3 toxicities despite the number of prior therapies. The ORR and manageable toxicity observed in this study supports further investigation of SV in this disease. No significant financial relationships to disclose.

  • Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): Follow-up results of a phase II study

    by M. A. Rodriguez, N. H. Dang, L. Fayad, A. Goy, F. B. Hagemeister, P. McLaughlin, B. Pro, J. E. Romaguera, A. Younes, F. Cabanillas

    8080 Background: Individuals older than 60 years have a worse prognosis than younger patients with aggressive NHL. Vincristine is active in malignant lymphomas. Sphingosomal vincristine (SV) was well tolerated with 45% ORR in multiply relapsed aggressive NHL (ASH Abst. 412, 1999). Based on these data, a phase II study of CHOP with or without rituximab, and substituting SV for free vincristine, was undertaken in patients with previously untreated aggressive NHL. Methods: Patients were treated with standard dose CHOP that included SV 2.0 mg/m2 without dose capping ± rituximab 375 mg/m2, given every 21 days for 6 to 8 courses (ASH abst. 338, 2002). Results: Of 73 patients enrolled on study, 68 were evaluable for response. Median age was 63 (range 22–80), 37 pts (54%) were > 60. Overall, 24 pts (23 elderly) had an IPI score ≥ 3. Patients received a median of 6 study treatments (range 1–8). ORR was 92.6% (63/68 pts) with 55 pts achieving CR (80.1%), 7 CRu (10.3%), and 1 PR (1.5%). 3 pts had PD (4.4%) and 2 were not assessed for response (2.9%). ORR was similar in both elderly (>60) and younger pts (≤ 60): 91.9% and 93.5% respectively. The median PFS and OS have not been reached at a median follow up of 22 months. The probability of being progression free at 17 mos was 0.88 (5 relapses) for elderly pts and 0.86 (4 relapses) for pts ≤ 60. Overall survival probability was 0.98 (1 death) at 22 mos. Neuropathy was generally mild (Gr.1-2). Hematological toxicities were as follows: 56% Gr.3-4 neutropenia, 6% Gr.3 anemia, and 13% Gr.3-4 thrombocytopenia. Toxicites were comparable in both elderly and younger patients. Conclusions: CHOP plus rituximab regimen with sphingosomal vincristine substituted for free vincristine is a well tolerated therapy with only mild neurotoxicity. Remarkably, the activity in the elderly is comparable to that in younger patients.


  • A randomized trial of CHOP chemotherapy with or without melatonin in patients with favorable prognosis large B-cell lymphoma

    by A. Sarma, M. A. Rodriguez, F. Cabanillas, N. H. Dang, P. McLaughlin, F. B. Hagemeister, B. Pro, J. Romaguera, A. Younes, E. A. Grimm

    8066 Background: Melatonin is a hormone made in the pineal gland that regulates sleep and influences other hormonal body functions. Studies by Lissoni, et al. (Supportive Care in Cancer. 5: 126,1997) also suggest a myeloprotective effect when administered with chemotherapy. To assess the myeloprotective effect of melatonin on patients receiving CHOP chemotherapy, we conducted the following trial. Methods: Eligible patients had newly diagnosed, histologically proven, large B-cell lymphoma with a favorable prognosis (M.D. Anderson Tumor Score<3. Rodriguez, et al. Ann Oncol. 3: 711–717, 1992). Patients were treated with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) every three weeks and were randomized to take or not to take melatonin 20 mg daily by mouth for 18 weeks starting on day 1 of course1. Weekly CBC's with differentials were obtained after cycle 1. The primary endpoint was the incidence of neutropenia (neutrophil count ≤ 500) after the first course of chemotherapy. Results: Between 1998 and 2001, 112 evaluable patients were enrolled on the study. 56 were randomized to each arm. Baseline characteristics were statistically similar between the groups. The median age was 54 and the International Prognostic Index score was ≤3 in 96% of patients. 51 patients experienced a neutrophil nadir ≤ 500 after course 1 of chemotherapy; 26 were in the arm with melatonin, 25 were in the arm without melatonin (p=0.78). Tests of association between the treatment group and secondary measured parameters including the nadir ANC, change in hemoglobin, change in platelet count, CR rate, and infection rate were not statistically significant. Overall survival was estimated to be 95% at three years in both arms. The three year failure-free survival was 75% in both treatment groups. Conclusions: The addition of melatonin to CHOP chemotherapy did not decrease the incidence of neutropenia after cycle 1 in this patient population. In addition, this study suggests that there is no improvement in neutrophil nadir, CR rate, infection rate, or change in hemoglobin or platelet counts with the addition of melatonin. No significant financial relationships to disclose.


  • Update on a phase (ph) 2 study of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin's lymphomas (NHL)

    by A. Goy, A. Younes, P. McLaughlin, B. Pro, J. Romaguera, F. Hagemeister, L. Fayad, E. G. Trehu, D. Schenkein, M. A. Rodriguez

    6581 Background: Proteasome inhibition disrupts many cell cycle checkpoints and pathways that lead to apoptosis. Preclinical and ph 1 studies suggested the proteasome inhibitor bortezomib (VELCADE™, Vc) was active in lymphoma. Methods: The primary objective of this ph 2 study was to document the response rate (RR) and toxicity of Vc in pts with relapsed or refractory NHL. Pts ≥ 16 yr, with relapsed or refractory mantle cell (MCL, gp A) or other B cell lymphomas (gp B) were eligible. Pts received Vc 1.5 mg/m2 IV on d1, 4, 8 and 11 q21d, were restaged q2 cycles, and treated for up to 6 cycles unless removed from study. Results:45 pts: 32 males, 13 females, median age 60 yr (range 45–81), were enrolled. There were 25 pts in gp A and 20 pts in gp B, including 10 diffuse large cell lymphoma (DLCL), 4 follicular lymphoma (FL), 3 transformed (t) FL, 2 small lymphocytic lymphoma (SLL), 1 Waldenström's macroglobulinemia (WM). Gp A had 3 median prior therapies (range 1–6); gp B had 4 (range 1–12). In gp A, of 21 evaluable (ev) pts, there were 11 responders: 3 CR, 1 CRu (unconfirmed CR), and 7 PR (RR = 52.3%), 2 MR, 2 no change (NC), 6 POD (progression of disease). Mean DOR (duration of response) was 5.7 mo (1.2–15 mo). In gp B, there were 8 ev DLCL with 1 PR (DOR 4 mo), 1 NC, 6 POD; 4 ev FL with 2 MR, 1 NC, 1 POD; 1 ev tFL with POD; 2 ev SLL with 1 NC, 1 POD; 1 WM pt had PR. Grade 3/4 toxicities were GI (5 pts), hypotension/fatigue (6 pts), neuropathy (1 pt with prior vinca/taxanes), and pneumonia (2 pts); hematologic toxicities were neutropenia (8) (only 1 pt with ANC <500) and thrombocytopenia (14 pt) (only 1 pt with platelets <10; most entered with platelets <30–50). 2 patients died: 1 had Cryptococcus meningitis, 1 had generalized zoster with encephalitis. Conclusions: This study showed remarkable activity of Vc in MCL and encouraging results in other B cell lymphomas. Future studies will include combinations of Vc with other chemotherapy and/or biological agents.